Diagnostic test for Alzheimers disease

Used for Produce a diagnostic report for Alzheimer’s disease to the cerebrospinal fluid provided to us


You need to login or register to bookmark/favorite this content.

Post author: Dementia Diagnostics Laboratory. Last update: 29/04/2016 at 2:42 pm by Tanya Mitchell.


Dr. Qiao-Xin Li

Phone: +61 3 9035 7243


Service overview

The National Dementia Diagnostics Laboratory (NDDL) located at the Florey Institute of Neuroscience and Mental Health, The University of Melbourne has been in operation since 2013. The NDDL offers NATA accredited diagnostic testing for Alzheimer’s disease and Creutzfeldt-Jakob disease, the only laboratory in Australia to offer this service. NDDL offers its diagnostic services to the medical community, scientific researchers and the pharmaceutical industry (NATA/RCPA accreditation #19256).

Additional info

The test provides Abeta1-42, Tau, and Phospho-tau quantification on cerebrospinal fluid (CSF) for Alzheimer’s Disease (NATA/RCPA accreditation #19256).
Based on international and our experience, these CSF biomarkers offer approximately ~90% sensitivity and specificity for clinically overt AD and valuable prognostic information in persons with amnestic mild cognitive impairment (Li et al. Alzheimer disease normative CSF biomarkers validated in PET Aβ characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimer’s Dis. 2015; 48:175–187; Hulstaet et al. Neurology 1999; 52:1555; Hansson et al., Lancet Neurol, 2006;5(3):228-34; Buchhave et al. Arch Gen Psychiatry 2012; 69: 98-106).


Capacity: We encourage greater utilisation
Operation: Facility provides the service for you
Access: Access by collaboration, Access by fee for service
Accreditation: ISO 15189